Announcing Exclusive Partnership with Visionix Italy Focused at Enhancing Eye Care Solutions in Italy

In the Press: on MedTech Outlook Espansione Group Named TOP Vision Care Solutions Provider in Europe

Announcing Exclusive Partnership with Rodenstock Norge AS Aimed at Elevating Eye Care Professionals in Norway

Announcing Exclusive Partnership Between Topcon Healthcare SEA and Espansione Group aimed at Driving Disruptive Innovation in Eye Care and Beyond in South-East Asia 

Announcing Exclusive Partnership Between Topcon Great Britain & Ireland and Espansione Group Aimed at Elevating Eye Care Innovation in Ocular Surface & Beyond

Espansione Group Announces the Appointment of a New Management Team Aimed at Granting Continuity in Cross-generational Leadership Exchange

Announcing Exclusive Partnership Between Essilor Instruments and Espansione Group Aimed at Offering Innovative Solutions in the USA and Canada

Espansione Group's Story Gets Featured on Harvard Business Review, Talking Strategy, Cross-generational Exchange and the New Leadership's Future Vision

Espansione Group's Leadership Amongst Forbes' 30 Under 30, Interview on Business Growth and Industry Outlook

Espansione Group, a pioneer in the medtech industry and an advocate for science-driven innovation, proudly shares the results of a recently published double-blinded, randomized and controlled investigation focusing on the prevention of surgery-induced dry eye in cataract patients.

Espansione Group, a pioneer in the medtech industry and an advocate for science-driven innovation, proudly unveils the first preliminary results of its recent multicentric, randomized controlled investigation: LightWave I.

We are thrilled to announce today the kick-off of the monocentric, randomized, simple bling, controlled clinical study on the efficiency of a combined Treatment With Pulsed Light and Photobiomodulation Before Laser Refractive Surgery (TEBELID).  

Light Modulation® LLLT technology has recently been studied in a piece of research in combination therapy with OPE® IPL tech.   The retrospective, monocentric study carried out in the Ophthalmology Department at Brest University Hospital, evaluates the efficacy and tolerance of intense pulsed light (IPL) therapy with low‐level light therapy (LLLT), our patented photo-biomodulation technology, in the treatment of meibomian gland dysfunction (MGD).

We’re proud to announce our Light Modulation® LLLT technology has recently been studied in a piece of research in combination therapy with OPE® IPL tech. The randomized, controlled, blinded study evaluates the efficacy of intense pulsed light (IPL) therapy with low‐level light therapy (LLLT) in the treatment of meibomian gland dysfunction (MGD) and evaporative dry eye (EDE) compared to a control group.

LightWave II is the second, global, multi-centric research effort to study patented photobiomodulation technology LM® LLLT for dry AMD management.
LightWave II is being announced today with the aim of strengthening the already existing body of research around PBM in AMD management.

Announcing our Partnership with Reykjavik University's Institute of biomedical and Neural Engineering

Light Modulation® LLLT technology is being employed in LightWave I, a multi-centric clinical trial on dry Age-releated Macular Degeneration. 

Our Light Modulation® LLLT technology has recently been studied in a piece of research comparing it directly against IPL tech.

A recent scientific paper has confirmed that our Light Modulation® LLLT technology, employed jointly with our Optimal Power Energy® IPL technology, is the key factor in effectively managing the most severe cases of recalcitrant MGD.